Anika Therapeutics Company Profile (NASDAQ:ANIK)

About Anika Therapeutics

Anika Therapeutics logoAnika Therapeutics, Inc. is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. Its therapeutic offerings consist of products in the areas, such as Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. It offers products made from HA based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Its orthobiologics products primarily consist of viscosupplementation and regenerative orthopedics products. Its viscosupplementation franchise includes ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Health Care Supplies
  • Exchange: NASDAQ
  • Symbol: ANIK
  • CUSIP: 03525510
Key Metrics:
  • Previous Close: $49.09
  • 50 Day Moving Average: $50.33
  • 200 Day Moving Average: $47.76
  • 52-Week Range: $41.38 - $54.96
  • Trailing P/E Ratio: 23.03
  • Foreward P/E Ratio: 25.68
  • P/E Growth: 2.44
  • Market Cap: $724.13M
  • Outstanding Shares: 14,626,000
  • Beta: 1.85
Profitability:
  • Net Margins: 33.64%
  • Return on Equity: 17.21%
  • Return on Assets: 15.71%
Debt:
  • Current Ratio: 21.25%
  • Quick Ratio: 18.87%
Additional Links:
Companies Related to Anika Therapeutics:

Analyst Ratings

Consensus Ratings for Anika Therapeutics (NASDAQ:ANIK) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $49.50 (0.14% downside)

Analysts' Ratings History for Anika Therapeutics (NASDAQ:ANIK)
Show:
DateFirmActionRatingPrice TargetDetails
4/27/2016Northland SecuritiesDowngradeOutperform -> Market PerformView Rating Details
2/26/2016Barrington ResearchBoost Price TargetOutperform$45.00 -> $49.00View Rating Details
8/27/2015First AnalysisInitiated CoverageEqual -> Equal WeightView Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Anika Therapeutics (NASDAQ:ANIK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2017        
2/15/2017Q416$0.53$0.54$27.84 million$28.70 millionViewN/AView Earnings Details
10/26/2016Q316$0.47$0.59$26.60 million$25.79 millionViewListenView Earnings Details
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/30/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anika Therapeutics (NASDAQ:ANIK)
Current Year EPS Consensus Estimate: $2.09 EPS
Next Year EPS Consensus Estimate: $1.93 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.19$0.25$0.22
Q2 20162$0.38$0.47$0.43
Q3 20162$0.46$0.47$0.47
Q4 20162$0.52$0.53$0.53
Q1 20172$0.34$0.42$0.38
Q2 20171$0.50$0.50$0.50
Q3 20172$0.50$0.51$0.51
Q4 20172$0.68$0.74$0.71
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anika Therapeutics (NASDAQ:ANIK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Anika Therapeutics (NASDAQ:ANIK)
Insider Ownership Percentage: 5.80%
Institutional Ownership Percentage: 76.53%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2016Joseph I BowerDirectorSell540$43.39$23,430.60View SEC Filing  
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.90View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Anika Therapeutics (NASDAQ:ANIK)
DateHeadline
sbwire.com logoWorldwide Hyaluronic Acid Market to Register $10.90 Bn by 2020 (NASDAQ:ANIK)
www.sbwire.com - February 23 at 1:39 AM
News IconGlobal Facial Rejuvenation Market is Anticipated to Grow US$ 26,585.6 Million by 2021 – Persistence Market Research (NASDAQ:ANIK)
www.medgadget.com - February 22 at 8:38 PM
News IconLooking at the Numbers for Anika Therapeutics, Inc. (NASDAQ:ANIK) - BVN (NASDAQ:ANIK)
bvnewsjournal.com - February 22 at 3:33 PM
News IconAutologous Matrix-Induced Chondrogenesis (AMIC) Market to Exceed US$ 186.4 Mn by the end of 2024 (NASDAQ:ANIK)
www.medgadget.com - February 22 at 11:30 AM
capitalcube.com logoAnika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 (NASDAQ:ANIK)
www.capitalcube.com - February 22 at 11:30 AM
News IconRising Awareness about Innovative and Less Painful Techniques and Rising Affordability Drives the Global Facial Rejuvenation Market (NASDAQ:ANIK)
reports.pr-inside.com - February 21 at 3:48 PM
News IconEurope Viscosupplementation Market Revenue to Reach US$ 327.2 Mn by 2026 (NASDAQ:ANIK)
www.medgadget.com - February 17 at 3:28 PM
News IconFollowing the Numbers on Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Benton Bulletin (NASDAQ:ANIK)
bentonbulletin.com - February 17 at 10:06 AM
finance.yahoo.com logoEdited Transcript of ANIK earnings conference call or presentation 16-Feb-17 2:00pm GMT (NASDAQ:ANIK)
finance.yahoo.com - February 17 at 10:06 AM
seekingalpha.com logoAnika Therapeutics Inc. 2016 Q4 - Results - Earnings Call Slides (NASDAQ:ANIK)
seekingalpha.com - February 16 at 3:36 PM
4-traders.com logoAnika Therapeutics : posts 4Q profit (NASDAQ:ANIK)
www.4-traders.com - February 16 at 8:26 AM
biz.yahoo.com logoQ4 2016 Anika Therapeutics Inc Earnings Release - After Market Close (NASDAQ:ANIK)
us.rd.yahoo.com - February 16 at 8:26 AM
us.rd.yahoo.com logoAnika Reports Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:ANIK)
us.rd.yahoo.com - February 16 at 8:26 AM
us.rd.yahoo.com logo4:09 pm Anika Therapeutics beats by $0.01, beats on revs; provides FY17 outlook (NASDAQ:ANIK)
us.rd.yahoo.com - February 16 at 8:26 AM
biz.yahoo.com logoANIKA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:ANIK)
us.rd.yahoo.com - February 16 at 8:26 AM
sg.finance.yahoo.com logoAnika posts 4Q profit (NASDAQ:ANIK)
sg.finance.yahoo.com - February 16 at 8:26 AM
News IconNorth America and Europe Dermal Filler Market will Increase at a CAGR of 6.4% during 2016–2026 (NASDAQ:ANIK)
www.satprnews.com - February 15 at 2:02 AM
News IconFacial Rejuvenation Market Expected to be Valued US$ 26,585.6 Million by 2021 (NASDAQ:ANIK)
www.medgadget.com - February 14 at 9:02 PM
News IconStock Update for Anika Therapeutics, Inc. (NASDAQ:ANIK ... - Sherwood Daily (NASDAQ:ANIK)
sherwooddaily.com - February 10 at 1:40 AM
investornewswire.com logoExpected For Anika Therapeutics Inc. (NASDAQ:ANIK) Sales Of $123.06 - Investor Newswire (NASDAQ:ANIK)
www.investornewswire.com - February 9 at 8:38 PM
openpr.com logoCosmetic Procedures and Products Market Research Report by Global Industry Growth, Trends and Forecast 2024 (NASDAQ:ANIK)
www.openpr.com - February 9 at 3:36 PM
biz.yahoo.com logoANIKA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:ANIK)
biz.yahoo.com - February 8 at 8:47 PM
streetinsider.com logoForm SC 13G/A Anika Therapeutics, Inc. Filed by: THOMPSON SIEGEL & WALMSLEY LLC - StreetInsider.com (NASDAQ:ANIK)
www.streetinsider.com - February 7 at 3:42 PM
News IconAnti-Adhesion Products Market: Latest Trends & Insights 2019 (NASDAQ:ANIK)
www.medgadget.com - February 6 at 8:22 PM
sbwire.com logoCompetitive Landscape for Non-Surgical Rejuvenation Market by Global Industry Segments - 2024 (NASDAQ:ANIK)
www.sbwire.com - February 4 at 1:43 AM
finance.yahoo.com logoNovo Nordisk (NVO) Misses Q4 Earnings, Revenues Down Y/Y (NASDAQ:ANIK)
finance.yahoo.com - February 3 at 3:42 PM
finance.yahoo.com logoNovo Nordisk (NVO) Misses Q4 Earnings, Revenues Down Y/Y (NASDAQ:ANIK)
finance.yahoo.com - February 3 at 3:42 PM
News IconROI of Heron Therapeutics, Inc. (NASDAQ:HRTX) stands at 0 (NASDAQ:ANIK)
xboxonezone.com - February 3 at 3:42 PM
News IconROI of Heron Therapeutics, Inc. (NASDAQ:HRTX) stands at 0 (NASDAQ:ANIK)
xboxonezone.com - February 3 at 3:42 PM
News IconGlobal Non Surgical Bio Implants Market Size, Share, Analysis Industry Growth and Forecast 2022 (NASDAQ:ANIK)
www.medgadget.com - February 3 at 1:38 AM
finance.yahoo.com logoCatabasis Hits 52-Week Low on Poor DMD Drug Study Data (NASDAQ:ANIK)
finance.yahoo.com - February 2 at 3:35 PM
finance.yahoo.com logoNovartis (NVS) Votubia Gets EU Approval for Label Expansion (NASDAQ:ANIK)
finance.yahoo.com - February 2 at 3:35 PM
finance.yahoo.com logoAnika to Issue Fourth-Quarter 2016 Financial Results and Business Highlights on Wednesday, February 15 (NASDAQ:ANIK)
finance.yahoo.com - February 1 at 8:41 PM
News IconTechnicals in Focus for Anika Therapeutics Inc. (ANIK) - Market Point (NASDAQ:ANIK)
mtptnews.com - February 1 at 3:40 PM
streetinsider.com logoForm 4 Anika Therapeutics, Inc. For: Jan 27 Filed by: Hague Richard - StreetInsider.com (NASDAQ:ANIK)
www.streetinsider.com - February 1 at 1:47 AM
realistinvestor.com logoDeferred Tax Assets Of Anika Therapeutics Inc. (NASDAQ:ANIK) At $1.4093 Millions - RealistInvestor.com (NASDAQ:ANIK)
www.realistinvestor.com - January 31 at 8:45 PM
News IconStock to Watch: Anika Therapeutics Inc. (ANIK) - Market Point (NASDAQ:ANIK)
mtptnews.com - January 31 at 3:45 PM
investornewswire.com logoAnika Therapeutics Inc. (NASDAQ:ANIK) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:ANIK)
www.investornewswire.com - January 30 at 8:56 PM
sbwire.com logoNew Growth of Hyaluronic Acid Products Market with Worldwide Industry Analysis to 2025 (NASDAQ:ANIK)
www.sbwire.com - January 30 at 3:55 PM
finance.yahoo.com logoCelgene (CELG) Gets Favorable CHMP Opinion for Revlimid (NASDAQ:ANIK)
finance.yahoo.com - January 30 at 3:55 PM
News IconInvestor Brief: Checking Technical Levels on Shares of Anika Therapeutics Inc. (ANIK) - Market Point (NASDAQ:ANIK)
mtptnews.com - January 29 at 8:33 PM
finance.yahoo.com logoAstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA (NASDAQ:ANIK)
finance.yahoo.com - January 27 at 9:23 PM
News IconNewly released market study: Viscosupplementation - Medical Devices Pipeline Assessment, 2016 (NASDAQ:ANIK)
reports.pr-inside.com - January 27 at 4:21 PM
us.rd.yahoo.com logoEndo (ENDP) Restructures its Branded Pharmaceutical Unit (NASDAQ:ANIK)
us.rd.yahoo.com - January 27 at 4:21 PM
us.rd.yahoo.com logoPfizer (PFE) C. Difficile Vaccine Positive in Phase II Study (NASDAQ:ANIK)
us.rd.yahoo.com - January 27 at 4:21 PM
News IconNew Market Report: Surgical Mesh - Medical Devices Pipeline Assessment, 2016 (NASDAQ:ANIK)
reports.pr-inside.com - January 27 at 1:56 AM
finance.yahoo.com logoVertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up (NASDAQ:ANIK)
finance.yahoo.com - January 26 at 3:50 PM
News IconTrend Strength Monitor on Shares of Anika Therapeutics Inc. (ANIK) - Springdale Times (NASDAQ:ANIK)
springdaletimes.com - January 26 at 1:44 AM
News IconShares in Focus: Anika Therapeutics, Inc. (NASDAQ:ANIK) - The Tribune (NASDAQ:ANIK)
lakecitytribune.com - January 25 at 8:43 PM
nasdaq.com logoHealthInvest Partners AB Buys Gilead Sciences Inc, McKesson Corp, Syneron Medical Ltd, Sells ... (NASDAQ:ANIK)
www.nasdaq.com - January 25 at 3:38 PM

Social

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Where is Anika Therapeutics' stock going? Where will Anika Therapeutics' stock price be in 2017?

2 brokers have issued 1-year price targets for Anika Therapeutics' shares. Their forecasts range from $49.00 to $50.00. On average, they expect Anika Therapeutics' share price to reach $49.50 in the next year.

When will Anika Therapeutics announce their earnings?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

Who owns Anika Therapeutics stock?

Anika Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (5.00%), Thompson Siegel & Walmsley LLC (3.41%), State Street Corp (2.17%), Renaissance Technologies LLC (1.14%), AQR Capital Management LLC (0.78%) and Russell Investments Group Ltd. (0.77%). Company insiders that own Anika Therapeutics stock include Joseph I Bower and Raymond J Land.

Who sold Anika Therapeutics stock? Who is selling Anika Therapeutics stock?

Anika Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Renaissance Technologies LLC, AQR Capital Management LLC, Oxford Asset Management, Federated Investors Inc. PA, Cadence Capital Management LLC, O Shaughnessy Asset Management LLC and New York State Teachers Retirement System. Company insiders that have sold Anika Therapeutics stock in the last year include Joseph I Bower and Raymond J Land.

Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?

Anika Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., FMR LLC, Two Sigma Investments LP, State Street Corp, A.R.T. Advisors LLC, Tudor Investment Corp Et Al, Allianz Asset Management AG and Ladenburg Thalmann Financial Services Inc..

How do I buy Anika Therapeutics stock?

Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Anika Therapeutics stock cost?

One share of Anika Therapeutics stock can currently be purchased for approximately $49.57.

Anika Therapeutics (NASDAQ:ANIK) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Earnings History Chart

Earnings by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Dividend History Chart

Dividend Payments by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Last Updated on 2/23/2017 by MarketBeat.com Staff